IRWD Positive Sentiment
Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation
Key Takeaway: Ironwood Pharmaceuticals has announced the publication of new Phase III data for linaclotide, targeting children and adolescents aged 6-17 years with functional constipation. The study was published in The Lancet Gastroenterology & Hepatology, highlighting the efficacy and safety of linaclotide in this age group. This development could enhance treatment options for pediatric patients.
Price reaction · baseline $12.76 (2024-01-08 close) · hit after-hours · clean, no other IRWD news in the window
day 0 close · peak
-2%
Market Sentiment Analysis
POSITIVE FACTORS
- New Phase III data published in a reputable journal.
- Focus on children and adolescents with functional constipation.
- Potential for improved treatment options in a younger demographic.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+57%
120-day peak, hindsight
Typical move
3.8%
average across 2 past catalysts
Lead asset
IW-3718
Phase 3 · Gastroesophageal Reflux Disease (GERD)
Frequently Asked Questions
What is the focus of the new linaclotide study?
The study focuses on children and adolescents aged 6-17 years with functional constipation.
Where was the linaclotide Phase III data published?
The data was published in The Lancet Gastroenterology & Hepatology.
What age group does the linaclotide study target?
The study targets children and adolescents aged 6 to 17 years.
What condition is linaclotide used to treat?
Linaclotide is used to treat functional constipation.